FinscoFinsco

Ascendis Pharma A/S (US.ASND)

Capital Allocation Audit · Period: 2012 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ASND · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion100.0%→
ROE129.0%→
Cash Conversion-1.2%→
D/E Ratio1.84→
Gross Margin92.9%↑
US.ASND (Ascendis Pharma A/S) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   100.0%    →
ROE              129.0%    →
Cash Conversion   -1.2%    →
D/E Ratio          1.84    →
Gross Margin      92.9%    ↑
Key Metrics
US.ASND (Ascendis Pharma A/S) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 100.0% →
ROE 129.0% →
Cash Conversion -1.2% →
D/E Ratio 1.84 →
Gross Margin 92.9% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies